Cullinan Therapeutics - CGEM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside: 38.95%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$23.03
▼ -1.1 (-4.56%)

This chart shows the closing price for CGEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cullinan Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEM

Analyst Price Target is $32.00
▲ +38.95% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cullinan Therapeutics in the last 3 months. The average price target is $32.00, with a high forecast of $40.00 and a low forecast of $26.00. The average price target represents a 38.95% upside from the last price of $23.03.

This chart shows the closing price for CGEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Cullinan Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00Low
5/16/2024HC WainwrightLower TargetBuy ➝ Buy$29.00 ➝ $28.00Low
5/16/2024WedbushReiterated RatingOutperform ➝ Outperform$36.00Low
5/1/2024Stifel NicolausInitiated CoverageBuy$40.00Low
4/17/2024JonestradingBoost TargetBuy ➝ Buy$22.00 ➝ $26.00Low
4/17/2024BTIG ResearchBoost TargetBuy ➝ Buy$20.00 ➝ $30.00N/A
4/16/2024HC WainwrightLower TargetBuy ➝ Buy$34.00 ➝ $29.00Low
4/15/2024William BlairInitiated CoverageOutperformLow
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00Low
2/15/2024WedbushInitiated CoverageOutperform$30.00Low
10/6/2023JonestradingInitiated CoverageBuy$22.00Low
8/11/2023HC WainwrightLower Target$39.00 ➝ $34.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00Low
6/15/2023TD CowenInitiated CoverageOutperformLow
5/12/2023HC WainwrightLower Target$50.00 ➝ $49.00Low
3/27/2023HC WainwrightReiterated RatingBuy$50.00Low
3/10/2023HC WainwrightReiterated RatingBuy$50.00Low
2/15/2023HC WainwrightReiterated RatingBuy$50.00Low
2/3/2023Morgan StanleyLower TargetOverweight$27.00 ➝ $19.00Low
11/21/2022BTIG ResearchInitiated CoverageBuyLow
5/17/2022HC WainwrightReiterated RatingBuy$50.00Low
3/18/2022HC WainwrightLower TargetBuy$55.00 ➝ $53.00High
2/8/2022SVB LeerinkReiterated RatingOutperformHigh
11/15/2021SVB LeerinkReiterated RatingBuy$54.00Low
6/7/2021Morgan StanleyBoost TargetOverweight$40.00 ➝ $43.00High
6/4/2021HC WainwrightBoost TargetBuy$48.00 ➝ $55.00Medium
6/4/2021SVB LeerinkBoost TargetOutperform$48.00 ➝ $54.00High
4/27/2021Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
4/26/2021Morgan StanleyBoost TargetEqual Weight ➝ Overweight$38.00 ➝ $40.00N/A
4/19/2021Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $40.00Medium
3/30/2021HC WainwrightBoost TargetBuy$47.00 ➝ $48.00Low
2/2/2021Morgan StanleyInitiated CoverageEqual Weight$38.00Low
2/2/2021Evercore ISIInitiated CoverageOutperform$55.00Low
2/2/2021SVB LeerinkInitiated CoverageOutperform$52.00N/A
2/1/2021HC WainwrightInitiated CoverageBuy$47.00Low
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/30/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/30/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/29/2024
  • 9 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 8 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 8 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $23.03
Low: $22.85
High: $24.99

50 Day Range

MA: $21.07
Low: $15.53
High: $29.35

52 Week Range

Now: $23.03
Low: $7.64
High: $30.19

Volume

698,778 shs

Average Volume

634,413 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cullinan Therapeutics?

The following Wall Street sell-side analysts have issued reports on Cullinan Therapeutics in the last year: BTIG Research, HC Wainwright, Jonestrading, Stifel Nicolaus, TD Cowen, Wedbush, and William Blair.
View the latest analyst ratings for CGEM.

What is the current price target for Cullinan Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Cullinan Therapeutics in the last year. Their average twelve-month price target is $32.00, suggesting a possible upside of 38.9%. Stifel Nicolaus has the highest price target set, predicting CGEM will reach $40.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of $26.00 for Cullinan Therapeutics in the next year.
View the latest price targets for CGEM.

What is the current consensus analyst rating for Cullinan Therapeutics?

Cullinan Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGEM will outperform the market and that investors should add to their positions of Cullinan Therapeutics.
View the latest ratings for CGEM.

What other companies compete with Cullinan Therapeutics?

How do I contact Cullinan Therapeutics' investor relations team?

The company's listed phone number is 617-410-4650 and its investor relations email address is [email protected]. The official website for Cullinan Therapeutics is www.cullinanoncology.com. Learn More about contacing Cullinan Therapeutics investor relations.